Zacks Investment Research on MSN
BMY vs GSK: Which biopharma giant has better prospects for now?
Bristol Myers Squibb BMY and GSK PLC GSK are among the largest global biopharma companies with broad and diverse portfolios.
GSK’s growth is increasingly specialty-led (HIV, RI&I, oncology), not just vaccines. ViiV’s long-acting injectables also tap into durable demand. Recent launches/approvals like Blenrep in r/r myeloma ...
CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results